Eupraxia Pharmaceuticals Prices US$55 Million Public Offering to Fund Clinical Development

summarizeSummary

Eupraxia Pharmaceuticals priced its public offering of common shares and pre-funded warrants, raising US$55 million to fund the continued development of its lead drug candidate, EP-104GI, and other pipeline initiatives.

check_boxKey Events

• Pricing of Public Offering

  Eupraxia Pharmaceuticals priced its public offering of 6,428,574 common shares at US$7.00 per share and 1,428,571 pre-funded warrants at US$6.99999 each, finalizing terms of the offering initiated on February 18, 2026.

• Secures US$55 Million in Gross Proceeds

  The offering is expected to generate approximately US$55 million in gross proceeds, before deducting underwriting commissions and estimated expenses.

• Funding for Clinical Development

  Net proceeds will primarily fund the continued advancement of EP-104GI for Eosinophilic Esophagitis, including preclinical studies, Phase 2 clinical trials, Phase 3 preparations, and manufacturing activities, as well as accelerating other gastrointestinal indications.

• Underwriter Option Granted

  The company granted underwriters a 30-day option to purchase up to an additional 1,178,571 common shares on the same terms.

auto_awesomeAnalysis

Eupraxia Pharmaceuticals has finalized the terms of its previously announced public offering, securing US$55 million in gross proceeds. This substantial capital raise, representing approximately 13.3% of the company's market capitalization, is critical for advancing its lead drug candidate, EP-104GI, through preclinical studies, Phase 2 clinical trials, and preparations for Phase 3. The offering, priced at a modest discount to the current market price, provides a significant runway for the company's clinical development efforts, especially following positive Phase 1b/2a data for EP-104GI reported on January 8, 2026. While dilutive, the funding is essential for a clinical-stage biotechnology company to progress its pipeline and prepare for potential commercialization.